FDA Approves Enhertu® for HER2-Low MBC
Read about the recent approval of Enhertu® for HER2-low MBC.
FDA Approves MARGENZA
On December 16, 2020, the FDA approved margetuximab-cmkb (MARGENZA®) in combination with chemotherapy, for treating metastatic HER2-positive breast cancer.
FDA Approves Keytruda®
On November 13, 2020, the FDA approved pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA approved test.
FDA Approves PHESGO
In late June, the FDA approved PHESGO (pertuzumab/ trastuzumab/ hyaluronidase-zzxf), a treatment that can be injected under the skin, to treat metastatic and early-stage HER2 positive breast cancer. Because it is given as an injection, PHESGO can be given by a healthcare professional in your home, and takes less time than an infusion.
New FDA Approval: A PI3K Inhibitor
The U.S. Food and Drug Administration (FDA) approved Piqray® for treating advanced breast cancer. Use the links below to learn more about the FDA approval and how PI3K inhibitors work and to find clinical trials on Metastatic Trial Search for Piqray and other therapies being tested in patients whose tumors have a PIK3CA mutation.